Johnson Johnson’s Biosense Webster buys medical device company Coherex Medical

Biosense Webster has acquired Coherex Medical, Inc. a privately held medical device company based in Salt Lake City, Utah.

As said in Johnson Johnson press release on Friday, Coherex Medical is focused on the development of the Coherex WaveCrest  Left Atrial Appendage (LAA) Occlusion System. This device is described as designed to permanently occlude the LAA in high-risk atrial fibrillation (Afib) patients to help reduce the incidence of stroke caused by the migration of blood clots formed in the LAA. It is recognized as the source of blood clots in approximately 90 percent of patients who have Afib.

“The addition of the Coherex WaveCrest System complements our comprehensive portfolio of therapeutic solutions for patients suffering from atrial fibrillation who not only suffer from reduced quality of life but also face a significantly greater risk of a stroke,” said Shlomi Nachman, Company Group Chairman.

“As the exclusive distributor of this system in regions outside of the U.S. since 2013, we are confident it will be well-differentiated in the market,” Nachman added.

Alex Martin, President and CEO, Coherex Medical, said: “The Coherex WaveCrest System offers substantial benefits for patients with atrial fibrillation who are at high risk for stroke, particularly for those who are contraindicated to anticoagulants and would therefore, be unprotected from the risk of cardio embolism.”

“We are excited that this technology will be coupled with Biosense Webster’s market leading therapies and look forward to bringing this innovative solution to more patients worldwide who stand to benefit from reduced risk of stroke.”

The Coherex WaveCrest LAA occlusion system received CE Mark in September 2013. It is not available for investigational use or commercial distribution in the U.S. at this time, Johnson Johnson noted in its press release.